Literature DB >> 3583210

Exercise hypertension: its measurement and evaluation.

I W Franz.   

Abstract

Blood pressure, the central parameter in the diagnosis of arterial hypertension, is subject to a high degree of variability. The dilemma for the evaluating physician is that he has no true value for the resting blood pressure that is both comparable and reproducible. Reproducibility, however, is an essential requirement for all diagnostic procedures in medicine. A standardized ergometric procedure (at workloads of 50 to 100 watts [W]; incremented 10 watts/min; cuff blood pressure measurements) is suitable to obtain comparable, reproducible monitoring of the blood pressure response in both pressure response in both normotensive subjects and hypertensive patients. The blood pressure behavior during and after ergometric exercise was investigated in 552 males in order to clarify if this standardized procedure is suitable for differentiating between normotensive subjects and hypertensive patients. The following normal upper limits for blood pressure values in men and women between the ages of 20 and 50 years of 200/100 mmHg (mean + 1 SD) at a workload of 100 W as well as 140/90 mmHg in the fifth minute of the recovery phase were obtained. Patients suffering from mild hypertension showed significantly (p less than 0.001) higher blood pressures (213 +/- 22/116 +/- 11 mmHg) at 100 W and after exercise than age-matched normotensives (188 +/- 14/92 +/- 9 mmHg) but significantly (p less than 0.001) lower values than hypertensives with stable hypertension (225 +/- 22/126 +/- 11 mmHg). Moreover, the systolic pressure response to ergometric work was significantly (p less than 0.05 to p less than 0.01) influenced by age. Using the normal upper limits for blood pressure during and after ergometry, the ergometric procedure revealed that 50% of the patients with borderline hypertension at rest could be classified as hypertensives. Their blood pressure response at 100 W (216 +/- 21/113 +/- 8 mmHg) did not significantly differ from the patients with mild hypertension. In contrast, in the 50% who reacted negatively to ergometric testing, the systolic blood pressure response at 100 W (204 +/- 18 mmHg) was significantly (p less than 0.01) lower than that of those who demonstrated a positive reaction, revealing exactly the same diastolic blood pressure value of 92 mmHg as the normotensives. Follow-up examinations several years (average 3.8 years) subsequently showed that 97% of the ergometric-positive borderline hypertensives developed established hypertension. Thus an early diagnosis of arterial hypertension was achieved years before its established manifestation.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1987        PMID: 3583210

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  5 in total

1.  Efficacy and safety of valsartan plus hydroclorothiazide for high blood pressure.

Authors:  Antonio Ruvolo; Valentina Mercurio; Valeria Fazio; Guido Carlomagno; Teresa Russo; Flora Affuso; Serafino Fazio
Journal:  World J Cardiol       Date:  2010-05-26

2.  Ergometry as a basis for judging the antihypertensive effect.

Authors:  I W Franz; U Tönnesmann; D Erb; R Ketelhut
Journal:  Drugs       Date:  1990       Impact factor: 9.546

3.  Blood pressure measurement guidelines for physical therapists.

Authors:  Ethel M Frese; Ann Fick; H Steven Sadowsky
Journal:  Cardiopulm Phys Ther J       Date:  2011-06

4.  Comparison of exercise-induced hypertension in low birth weight and normal birth weight young black adults in Zimbabwe.

Authors:  Jephat Chifamba; Kudakwashe E Chakanyuka; Benjamin Longo-Mbenza; Carol B Mahachi; Jacob Mufunda
Journal:  High Blood Press Cardiovasc Prev       Date:  2012-09-01

5.  Association of Cardiorespiratory Fitness and Hemodynamic Responses to Submaximal Exercise Testing With the Incidence of Chronic Kidney Disease: The Framingham Heart Study.

Authors:  Joowon Lee; Rebecca J Song; Ramachandran S Vasan; Vanessa Xanthakis
Journal:  Mayo Clin Proc       Date:  2020-06       Impact factor: 7.616

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.